RLS-0071 is a dual targeting anti-inflammatory peptide that inhibits complement and inflammatory processes such as neutrophil activation and NETosis RLS-0071 is in development for treatment of […]

RLS-0071 positioned as a novel pharmacological intervention to improve survival and cognitive outcomes for newborns affected by devastating disease Norfolk, VA, December 3, 2020 — ReAlta […]

Norfolk, Virginia, known globally for its expertise in resilience and strong entrepreneurship ecosystem, is emerging as a tech hub for companies supporting products, technologies and services […]

The Virginia Pilot | November 16, 2020 https://www.pilotonline.com/inside-business/vp-ib-realta-covid-update-1109-20201116-hkwsno4uencqvbq7tjidj7alva-story.html

Norfolk, VA, October 20, 2020 — ReAlta Life Sciences, Inc., today announced the details of a formal ribbon-cutting ceremony at their new headquarters located at 5665 Lowery Road, […]

Phase 1 Trial for the Treatment of Patients with Acute Lung Injury Due to COVID 19 Anticipated to Begin in Third Quarter of 2020 Norfolk, VA, […]

Norfolk, VA, June 29, 2020 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive Officer, is scheduled to participate in […]

ReAlta Life Sciences is pleased to have received a Commonwealth Research Commercialization Fund (CRCF) grant. This award will help support the clinical development of ReAlta’s lead […]

Norfolk, VA, May 28, 2020 — ReAlta Life Sciences, Inc. announced today that it will participate in the upcoming virtual BIO International Convention, BIO Digital, being held June 8 – 12, […]

Proceeds to Fund Advancement of Programs Addressing Acute Lung Injury Due to COVID-19 and Severe Birth Asphyxia (HIE) Norfolk, VA, April 21, 2020 — ReAlta Life […]